{
  "id": 2160092,
  "title": "Today: Die gefährliche Schuldenwette der USA",
  "url": "https://urgent.news/2026/08/20/today-die-gefahrliche-schuldenwette-der-usa",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-20T14:58:21.000Z",
  "source": {
    "name": "Handelsblatt",
    "slug": "handelsblatt",
    "url": "https://www.handelsblatt.com/audio/today/today-die-gefaehrliche-schuldenwette-der-usa/100248665.html"
  },
  "original_language": "de",
  "account": "This week, global investors have been most concerned about uncertainty in bond markets. US Treasury bonds with a 30-year maturity reached their highest yield since 2007 at 5.34 percent. In response to this development, US Treasury Secretary Scott Bessent announced a doubling of the buyback volume for papers with maturities between ten and 30 years. This initially brought a sense of relief, but it does not address a structural problem - the way the United States finances its sovereign debt.\n\nAntonia Mannweiler, US correspondent for Handelsblatt Today, explains why the underlying mechanism poses a significant risk to financial markets. The article also examines the dramatic rise in Moderna's stock price after the US biotech company announced a study success for a new cancer vaccine. The stock's gain reached 177 percent at one point on Wednesday. Markus Manns, senior portfolio manager at Union Investment, discusses in a podcast how justified investor euphoria is.",
  "summary": "Die USA finanzieren ihre Schulden zunehmend über kurzlaufende Schuldtitel. Für die Finanzmärkte ist das riskant. Und: Wie Moderna von einem Krebsimpfstoff profitieren könnte.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}